Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

256 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial.
van der Voort A, van Ramshorst MS, van Werkhoven ED, Mandjes IA, Kemper I, Vulink AJ, Oving IM, Honkoop AH, Tick LW, van de Wouw AJ, Mandigers CM, van Warmerdam LJ, Wesseling J, Vrancken Peeters MT, Linn SC, Sonke GS. van der Voort A, et al. Among authors: sonke gs. JAMA Oncol. 2021 Jul 1;7(7):978-984. doi: 10.1001/jamaoncol.2021.1371. JAMA Oncol. 2021. PMID: 34014249 Free PMC article. Clinical Trial.
Isolated tumor cells in breast cancer.
Sonke GS, Linn SC. Sonke GS, et al. N Engl J Med. 2009 Nov 12;361(20):1995; author reply 1995-6. N Engl J Med. 2009. PMID: 19911470 No abstract available.
Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer.
Lips EH, Mukhtar RA, Yau C, de Ronde JJ, Livasy C, Carey LA, Loo CE, Vrancken-Peeters MJ, Sonke GS, Berry DA, Van't Veer LJ, Esserman LJ, Wesseling J, Rodenhuis S, Shelley Hwang E; I-SPY TRIAL Investigators. Lips EH, et al. Among authors: sonke gs. Breast Cancer Res Treat. 2012 Nov;136(1):35-43. doi: 10.1007/s10549-012-2233-z. Epub 2012 Sep 8. Breast Cancer Res Treat. 2012. PMID: 22961065 Free PMC article.
SERPINA6, BEX1, AGTR1, SLC26A3, and LAPTM4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancer.
de Ronde JJ, Lips EH, Mulder L, Vincent AD, Wesseling J, Nieuwland M, Kerkhoven R, Vrancken Peeters MJ, Sonke GS, Rodenhuis S, Wessels LF. de Ronde JJ, et al. Among authors: sonke gs. Breast Cancer Res Treat. 2013 Jan;137(1):213-23. doi: 10.1007/s10549-012-2340-x. Epub 2012 Dec 1. Breast Cancer Res Treat. 2013. PMID: 23203637
Guiding breast-conserving surgery in patients after neoadjuvant systemic therapy for breast cancer: a comparison of radioactive seed localization with the ROLL technique.
Donker M, Drukker CA, Valdés Olmos RA, Rutgers EJ, Loo CE, Sonke GS, Wesseling J, Alderliesten T, Vrancken Peeters MJ. Donker M, et al. Among authors: sonke gs. Ann Surg Oncol. 2013 Aug;20(8):2569-75. doi: 10.1245/s10434-013-2921-x. Epub 2013 Mar 6. Ann Surg Oncol. 2013. PMID: 23463088
Treatment of HER2-positive metastatic breast cancer.
van Ramshorst MS, Sonke GS. van Ramshorst MS, et al. Among authors: sonke gs. N Engl J Med. 2015 May 14;372(20):1964. doi: 10.1056/NEJMc1503446. N Engl J Med. 2015. PMID: 25970057 No abstract available.
256 results